Vamil Divan
Stock Analyst at Guggenheim
(4.63)
# 184
Out of 4,944 analysts
230
Total ratings
65.43%
Success rate
15.71%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $216 → $227 | $198.64 | +14.28% | 27 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $164 → $167 | $172.78 | -3.35% | 16 | Jul 17, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.24 | +212.50% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $7.39 | +89.45% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.58 | +210.08% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $284.98 | +1.06% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $88.34 | -2.65% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $9.40 | +48.94% | 1 | May 8, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $4.25 | +1,311.76% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $80.30 | +43.21% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $17.41 | +169.96% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $23.91 | +29.65% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.97 | +236.70% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.65 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $21.14 | +188.55% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $122.00 | -17.21% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.72 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.59 | +4,321.77% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.86 | +946.63% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.93 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $25.45 | -25.34% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $128.89 | -23.97% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $27.43 | +23.95% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.33 | +651.88% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $105.23 | -53.44% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $639.43 | -44.33% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.30 | -17.81% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $13.47 | +1,043.28% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.40 | +134.38% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.66 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $16.60 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.50 | +233.33% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $46.55 | +31.04% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.79 | +5,654.19% | 3 | Jan 17, 2018 |
AbbVie
Aug 1, 2025
Maintains: Buy
Price Target: $216 → $227
Current: $198.64
Upside: +14.28%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $164 → $167
Current: $172.78
Upside: -3.35%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.24
Upside: +212.50%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $7.39
Upside: +89.45%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.58
Upside: +210.08%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $284.98
Upside: +1.06%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $88.34
Upside: -2.65%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $9.40
Upside: +48.94%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.25
Upside: +1,311.76%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $80.30
Upside: +43.21%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $17.41
Upside: +169.96%
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $23.91
Upside: +29.65%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.97
Upside: +236.70%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.65
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $21.14
Upside: +188.55%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $122.00
Upside: -17.21%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.72
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.59
Upside: +4,321.77%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.86
Upside: +946.63%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.93
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $25.45
Upside: -25.34%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $128.89
Upside: -23.97%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $27.43
Upside: +23.95%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.33
Upside: +651.88%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $105.23
Upside: -53.44%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $639.43
Upside: -44.33%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.30
Upside: -17.81%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $13.47
Upside: +1,043.28%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.40
Upside: +134.38%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.66
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $16.60
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.50
Upside: +233.33%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $46.55
Upside: +31.04%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.79
Upside: +5,654.19%